Galectin Therapeutics Stock Total Debt
| GALT Stock | USD 1.60 0.03 1.91% |
Galectin Therapeutics fundamentals help investors to digest information that contributes to Galectin Therapeutics' financial success or failures. It also enables traders to predict the movement of Galectin Stock. The fundamental analysis module provides a way to measure Galectin Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Galectin Therapeutics stock.
Total Debt To Capitalization is likely to gain to 5.87 in 2025.
Galectin | Total Debt |
Galectin Therapeutics Company Total Debt Analysis
Galectin Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Galectin Therapeutics Total Debt | 71.81 M |
Most of Galectin Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Galectin Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Galectin Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Galectin Therapeutics is extremely important. It helps to project a fair market value of Galectin Stock properly, considering its historical fundamentals such as Total Debt. Since Galectin Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Galectin Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Galectin Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Galectin Total Debt Historical Pattern
Today, most investors in Galectin Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Galectin Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Galectin Therapeutics total debt as a starting point in their analysis.
Galectin Therapeutics Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Galectin Short Long Term Debt Total
Short Long Term Debt Total |
|
At this time, Galectin Therapeutics' Short and Long Term Debt Total is comparatively stable compared to the past year.
Based on the latest financial disclosure, Galectin Therapeutics has a Total Debt of 71.81 M. This is 97.39% lower than that of the Biotechnology sector and 77.89% lower than that of the Health Care industry. The total debt for all United States stocks is 98.65% higher than that of the company.
Galectin Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Galectin Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Galectin Therapeutics could also be used in its relative valuation, which is a method of valuing Galectin Therapeutics by comparing valuation metrics of similar companies.Galectin Therapeutics is currently under evaluation in total debt category among its peers.
Galectin Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Galectin Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Galectin Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Galectin Therapeutics' value.| Shares | |||
| Retirement Guys Formula Llc | 2024-12-31 | 155.3 K | |
| Soltis Investment Advisors, Llc | 2024-12-31 | 140.8 K | |
| Lpl Financial Corp | 2024-12-31 | 138.9 K | |
| Commonwealth Equity Services Inc | 2024-12-31 | 134.5 K | |
| Cambridge Invest Research Advisors, Inc. | 2024-12-31 | 118.6 K | |
| Cutter & Co Brokerage, Inc. | 2024-12-31 | 115.5 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 65.1 K | |
| Jpmorgan Chase & Co | 2024-12-31 | 59.7 K | |
| Sanctuary Advisors, Llc | 2024-12-31 | 58.4 K | |
| Vanguard Group Inc | 2024-12-31 | 2.1 M | |
| Blackrock Inc | 2024-12-31 | 1.7 M |
Galectin Fundamentals
| Return On Equity | -37.28 | ||||
| Return On Asset | -0.97 | ||||
| Current Valuation | 178.91 M | ||||
| Shares Outstanding | 62.76 M | ||||
| Shares Owned By Insiders | 31.23 % | ||||
| Shares Owned By Institutions | 16.23 % | ||||
| Number Of Shares Shorted | 7.72 M | ||||
| Price To Earning | (4.21) X | ||||
| Price To Book | 207.70 X | ||||
| EBITDA | (202 K) | ||||
| Net Income | (41.07 M) | ||||
| Cash And Equivalents | 15.83 M | ||||
| Cash Per Share | 0.27 X | ||||
| Total Debt | 71.81 M | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | (1.52) X | ||||
| Cash Flow From Operations | (32.97 M) | ||||
| Short Ratio | 29.52 X | ||||
| Earnings Per Share | (0.73) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 14 | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 98.54 M | ||||
| Total Asset | 28.2 M | ||||
| Retained Earnings | (354.37 M) | ||||
| Working Capital | 12.03 M | ||||
| Current Asset | 26.4 M | ||||
| Current Liabilities | 1.36 M | ||||
| Net Asset | 28.2 M |
About Galectin Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Galectin Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galectin Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galectin Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.